Colorectal Carcinoma

Oncology
9
Pipeline Programs
11
Companies
11
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
3
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Auron Therapeutics
1 program
1
AMT2003Phase 2/31 trial
Active Trials
NCT00405561TerminatedEst. Jan 2010
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
IMC-1121BPhase 21 trial
Active Trials
NCT00862784Completed48Est. Aug 2011
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1706Phase 21 trial
Active Trials
NCT05799820UnknownEst. Sep 2025
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
encorafenib + cetuximab + FOLFIRIPhase 21 trial
Active Trials
NCT06640166RecruitingEst. Jun 2026
Biogen
BiogenCAMBRIDGE, MA
1 program
1
Ad.hIFN-βPhase 1/21 trial
Active Trials
NCT00107861Completed44Est. Sep 2006
IB
Immatics BiotechnologiesGermany - Munich
1 program
1
Endoxana, Leukine, IMA910Phase 1/21 trial
Active Trials
NCT00785122Completed92Est. May 2013
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
JX-594Phase 1/21 trial
Active Trials
NCT01394939CompletedEst. Oct 2015
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 765049Phase 11 trial
Active Trials
NCT06882746Recruiting135Est. May 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
re-activated T cellsPhase 11 trial
Active Trials
NCT02577588Terminated1Est. Feb 2018
EXACT Therapeutics
EXACT TherapeuticsNorway - Oslo
1 program
Biospecimen CollectionN/A1 trial
Active Trials
NCT05410977Recruiting750Est. Apr 2027
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Fecal Immunochemical TestN/A1 trial
Active Trials
NCT04890054Completed5,696Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Auron TherapeuticsAMT2003
Pierre Fabreencorafenib + cetuximab + FOLFIRI
Qilu PharmaceuticalQL1706
Eli Lilly and CompanyIMC-1121B
TransgeneJX-594
Immatics BiotechnologiesEndoxana, Leukine, IMA910
BiogenAd.hIFN-β
Boehringer IngelheimBI 765049
Heidelberg Pharmare-activated T cells
EXACT TherapeuticsBiospecimen Collection
Knight TherapeuticsFecal Immunochemical Test

Clinical Trials (11)

Total enrollment: 6,766 patients across 11 trials

NCT00405561Auron TherapeuticsAMT2003

Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003

Start: Oct 2006Est. completion: Jan 2010
Phase 2/3Terminated
NCT06640166Pierre Fabreencorafenib + cetuximab + FOLFIRI

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Start: Jun 2024Est. completion: Jun 2026
Phase 2Recruiting
NCT05799820Qilu PharmaceuticalQL1706

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Start: Sep 2022Est. completion: Sep 2025
Phase 2Unknown
NCT00862784Eli Lilly and CompanyIMC-1121B

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

Start: Apr 2009Est. completion: Aug 201148 patients
Phase 2Completed
NCT01394939TransgeneJX-594

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Start: Jan 2012Est. completion: Oct 2015
Phase 1/2Completed
NCT00785122Immatics BiotechnologiesEndoxana, Leukine, IMA910

IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)

Start: Jun 2008Est. completion: May 201392 patients
Phase 1/2Completed
NCT00107861BiogenAd.hIFN-β

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Start: May 2005Est. completion: Sep 200644 patients
Phase 1/2Completed
NCT06882746Boehringer IngelheimBI 765049

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Start: Mar 2025Est. completion: May 2027135 patients
Phase 1Recruiting
NCT02577588Heidelberg Pharmare-activated T cells

Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer

Start: May 2016Est. completion: Feb 20181 patients
Phase 1Terminated
NCT05410977EXACT TherapeuticsBiospecimen Collection

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

Start: Mar 2022Est. completion: Apr 2027750 patients
N/ARecruiting
NCT04890054Knight TherapeuticsFecal Immunochemical Test

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC

Start: May 2021Est. completion: Jul 20245,696 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 6,766 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)